In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, South Korea and Taiwan.
An interesting development in this age of Irish-fueled tax inversion deals, the Mayo Clinic and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.
Shire has signed a $225 million agreement to brighten its future in rare diseases, bolstering a major selling point for AbbVie as the two prepare for a $54.7 billion merger.
The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
Quest Diagnostics' partnership deal with a state-of-the-art French company is showing signs of paying off.
Startup Neurotrope is teaming up with the Icahn School of Medicine at Mount Sinai in New York City to further develop its bryostatins for the treatment of Niemann-Pick disease type C, a rare disease that mostly affects children.
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
AstraZeneca has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely-watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.
Months removed from getting bought by Huntingdon Life Sciences, Harlan Laboratories has teamed up with a French CRO to expand its capabilities in drug discovery and translational medicine.